Merck MRK is expected to face some notable headwinds over the next few years that could affect its long-term growth outlook, ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase ...

Merck says Keytruda plus Padcev improved survival and response rates versus chemotherapy in a Phase 3 muscle-invasive bladder ...

Merck (MRK) just cleared an important clinical hurdle, reporting strong Phase 3 KEYNOTE B15 results showing that KEYTRUDA ...

Halozyme is seeing some progress in its global effort to defend intellectual property against alleged infringement by Merck & ...

BMO Capital Markets upgraded to Outperform from Market Perform and raised its price target to $130 from $82 on Thursday, ...

In a setback for Merck, a German court issued a preliminary injunction that prevents the company from distributing a new subcutaneous formulation of ...

While acknowledging that Keytruda’s loss of exclusivity in 2028 represents the largest patent cliff in biopharma, BMO said it ...

Merck (MRK) stock is a buy as Q3 beats estimates, driven by Keytruda, pipeline growth, and strong technicals. Read here for more analysis.

The combination of Keytruda and Padcev is taking another major step toward securing its position as a leading therapy in the ...

We recently published 12 Stocks on Jim Cramer’s Radar . Merck & Co., Inc. (NYSE:MRK) is one of the stocks on Jim Cramer’s ...

This degree of success can become a double-edged sword, though. While the drug has thrived since its first approval back in ...